# A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)

> **NCT00257608** · PHASE3 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 1145 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** bevacizumab
- **DRUG:** placebo
- **DRUG:** erlotinib HCl

## Key facts

- **NCT ID:** NCT00257608
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 1145 (ACTUAL)
- **Last updated:** 2016-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00257608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00257608, "A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)". Retrieved via MORVS 2026-11-03 from https://api.morvs.ai/clinical/NCT00257608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*